{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PSMA-positive+Metastatic+Castration-resistant+Prostate+Cancer+%28mCRPC%29", "query": { "condition": "PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PSMA-positive+Metastatic+Castration-resistant+Prostate+Cancer+%28mCRPC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T02:11:35.816Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 26, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT03511664", "title": "Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "Best supportive/best standard of care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 861, "start_date": "2018-05-29", "completion_date": "2023-12-14", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 45, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 34 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511664" }, { "nct_id": "NCT06780670", "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Investigators choice of SoC", "type": "DRUG" }, { "name": "AAA817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 443, "start_date": "2025-02-27", "completion_date": "2033-07-19", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 35, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780670" }, { "nct_id": "NCT07047118", "title": "A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Cancer, Castration-Resistant" ], "interventions": [ { "name": "JSB462", "type": "DRUG" }, { "name": "AAA617", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 138, "start_date": "2025-07-03", "completion_date": "2028-05-14", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 10, "location_summary": "Duarte, California • Santa Monica, California • Denver, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07047118" }, { "nct_id": "NCT06894511", "title": "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "ARPI: Abiraterone", "type": "DRUG" }, { "name": "ARPI: Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 7, "start_date": "2025-09-11", "completion_date": "2026-10-15", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 5, "location_summary": "Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more", "locations": [ { "city": "Casa Grande", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06894511" }, { "nct_id": "NCT06033001", "title": "Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "overall_status": "TEMPORARILY_NOT_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Castration-Resistant Prostatic Cancer" ], "interventions": [ { "name": "[Lu-177]-PNT2002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantheus Medical Imaging", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 7, "location_summary": "Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Trinity", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06033001" }, { "nct_id": "NCT07226986", "title": "A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy" ], "interventions": [ { "name": "AMO959", "type": "DRUG" }, { "name": "AAA617", "type": "RADIATION" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 123, "start_date": "2025-12-05", "completion_date": "2029-09-13", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 3, "location_summary": "Los Angeles, California • El Paso, Texas • Murray, Utah", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "El Paso", "state": "Texas" }, { "city": "Murray", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226986" }, { "nct_id": "NCT06972628", "title": "Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Prostate Cancer Patients With Bone Metastasis", "Prostate Cancer (CRPC)", "Prostate Cancer", "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Administering Lutetium-177-PSMA-617 (PLUVICTO)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ebrahim S Delpassand", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2025-05-23", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06972628" }, { "nct_id": "NCT06004661", "title": "Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "68Ga-PSMA-11", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 23, "start_date": "2024-04-04", "completion_date": "2026-12-14", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06004661" }, { "nct_id": "NCT06855277", "title": "Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AAA817", "type": "DRUG" }, { "name": "ARPI", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 940, "start_date": "2025-07-01", "completion_date": "2032-11-04", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-04T02:11:35.816Z", "location_count": 38, "location_summary": "Homewood, Alabama • Orange, California • Palo Alto, California + 33 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855277" } ] }